Wei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wei Chen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Changming Yu
Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China
1 shared publicationLei Dong
Clinical Laboratory Center, PLA Air Force General Hospital, Haidian, Beijing 100142
1 shared publicationLihua Hou
Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China
1 shared publicationLing Fu
Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China
1 shared publication- Shaoqiong Yi
Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China
1 shared publication Shuling Liu
Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China
1 shared publication
Latest Publications
- Open Access
- 13 September 2013
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 6 (5) , 1208-1212
Monitoring luciferase-labeled human prostate stem cell antigen-expressing tumor growth in a mouse model
The aim of this study was to establish a tumor model in mice with the expression of luciferase (Luc) and human prostate stem cell antigen (PSCA), in order to evaluate the activities of anticancer drugs or vaccines for prostate cancer. RM-1 cells were stably transfected with pcDNA-Luc and pcDNA-PSCA plasmids. The Luc-expressing cells were examined using a luminometer and the PSCA-expressing cells were examined using a reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometric analysis. Male C57BL/6 mice were inoculated subcutaneously with the RM-PSCA/Luc cells, prior to the tumor growth and survival time of the mice being measured, respectively. In vivo bioluminescence imaging was used to detect Luc expression and immunohistochemical analysis was used to detect PSCA expression. Inoculation of the tumor cells into the C57BL/6 mice closely mimicked the tumor growth of prostate cancer. All of the inoculated mice exhibited a detectable tumor within two weeks. Tumor progression was able to be quantitatively monitored following the inoculation of 1×106 RM-PSCA/Luc cells. There was an excellent correlation (R2=0.9849) between the photon counts and tumor volume. The expression of PSCA in tumor tissues was confirmed using immunohistochemical analysis. The Luc and PSCA co-expression tumor model was successfully established in mice, which is likely to accelerate the understanding of the pathogenesis of prostate cancer and facilitate the development of novel antitumor drugs or vaccines for the disease.
- 13 September 2013
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 6 (5) , 1208-1212
Open AccessMonitoring luciferase-labeled human prostate stem cell antigen-expressing tumor growth in a mouse model
The aim of this study was to establish a tumor model in mice with the expression of luciferase (Luc) and human prostate stem cell antigen (PSCA), in order to evaluate the activities of anticancer drugs or vaccines for prostate cancer. RM-1 cells were stably transfected with pcDNA-Luc and pcDNA-PSCA plasmids. The Luc-expressing cells were examined using a luminometer and the PSCA-expressing cells were examined using a reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometric analysis. Male C57BL/6 mice were inoculated subcutaneously with the RM-PSCA/Luc cells, prior to the tumor growth and survival time of the mice being measured, respectively. In vivo bioluminescence imaging was used to detect Luc expression and immunohistochemical analysis was used to detect PSCA expression. Inoculation of the tumor cells into the C57BL/6 mice closely mimicked the tumor growth of prostate cancer. All of the inoculated mice exhibited a detectable tumor within two weeks. Tumor progression was able to be quantitatively monitored following the inoculation of 1×106 RM-PSCA/Luc cells. There was an excellent correlation (R2=0.9849) between the photon counts and tumor volume. The expression of PSCA in tumor tissues was confirmed using immunohistochemical analysis. The Luc and PSCA co-expression tumor model was successfully established in mice, which is likely to accelerate the understanding of the pathogenesis of prostate cancer and facilitate the development of novel antitumor drugs or vaccines for the disease.